Mumbai, Sep 18 (UNI) Pharma major, Dr Reddy's Labs announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 pc and 0.1 pc, the storebrand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).
Dr Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 pc and 0.1 pc are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 pc is also indicated for the temporary relief of red eyes.
"This launch marks the entry of Dr Reddy's into the OTC eye care space, and is a testament to our deep capabilities in bringing store-brand equivalents of Rx-to-OTC switches to the U.S. market," says Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories. "We are very excited to extend our strategic collaboration with Gland Pharma to bring these products to the market. We thank the teams at Gland and Dr. Reddy's whose hard work and efforts have enabled the execution of this launch in such a short timeframe."
The Pataday brand had US sales of approximately $31 million since the launch in March 2020 according to IRi.
Dr Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 pc is available in a 2.5 mL bottle and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 pc is available in a 5 mL bottle size.
Pataday is a registered trademark of Novartis AG.
UNI JS SB 1220